25,992 Shares in Repligen Corporation $RGEN Acquired by Bank of Nova Scotia

Key Points

• Bank of Nova Scotia acquired 25,992 Repligen shares in the second quarter, valued at approximately $3.55 million. Institutional investors collectively own 97.64% of the company.
• Repligen beat quarterly expectations with adjusted earnings of $0.54 per share versus the $0.45 consensus estimate, while revenue rose 11.9% year over year to $204.13 million.
• Analyst sentiment is broadly positive: Repligen has a consensus “Buy” rating and a $166.43 average price target, although the stock’s valuation remains elevated at a price-to-earnings ratio of 248.89.

Bank of Nova Scotia acquired a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 25,992 shares of the biotechnology company's stock, valued at approximately $3,547,000.

Several other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its position in shares of Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company's stock worth $753,603,000 after buying an additional 1,091,683 shares during the last quarter. United Capital Financial Advisors LLC acquired a new position in shares of Repligen in the 3rd quarter valued at $368,387,000. Opti Capital Management LP purchased a new position in shares of Repligen in the 4th quarter valued at $2,399,209,000. Wasatch Advisors LP grew its position in shares of Repligen by 27.9% in the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company's stock valued at $216,974,000 after buying an additional 346,720 shares during the last quarter. Finally, Maverick Capital Ltd. acquired a new stake in Repligen during the 1st quarter worth $178,946,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Repligen news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.60% of the company's stock.

Repligen Stock Up 0.0%

RGEN opened at $181.69 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The company has a market cap of $10.25 billion, a price-to-earnings ratio of 248.89, a PEG ratio of 3.31 and a beta of 1.03. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73. The business's fifty day moving average is $149.17 and its two-hundred day moving average is $132.22.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts anticipate that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on RGEN. Benchmark upgraded shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. Wolfe Research initiated coverage on shares of Repligen in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $145.00 price objective on the stock. Jefferies Financial Group reaffirmed a "hold" rating and issued a $142.00 target price on shares of Repligen in a report on Tuesday, May 5th. JPMorgan Chase & Co. increased their target price on shares of Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Finally, Zacks Research raised Repligen from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 30th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Repligen has a consensus rating of "Buy" and a consensus target price of $166.43.

Repligen Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source